2003
DOI: 10.1016/s0014-827x(03)00022-3
|View full text |Cite
|
Sign up to set email alerts
|

Structural modifications of antisense oligonucleotides

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

1
48
0

Year Published

2005
2005
2020
2020

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 87 publications
(49 citation statements)
references
References 29 publications
1
48
0
Order By: Relevance
“…The combination of nucleotides with aminoalkyl chains greatly enhances the variety of possible structures as well as their potential application [24]. Thus, oligonucleotides possessing cationic functionalities in addition to the anionic phosphate backbone have been shown to exhibit promising properties [25][26][27][28]. Polyamines, putrescine, spermine and spermidine, are involved in the regulation of gene function [29,30].…”
Section: Introductionmentioning
confidence: 99%
“…The combination of nucleotides with aminoalkyl chains greatly enhances the variety of possible structures as well as their potential application [24]. Thus, oligonucleotides possessing cationic functionalities in addition to the anionic phosphate backbone have been shown to exhibit promising properties [25][26][27][28]. Polyamines, putrescine, spermine and spermidine, are involved in the regulation of gene function [29,30].…”
Section: Introductionmentioning
confidence: 99%
“…Most of the improvements in the design of nucleic acid derivatives aim to enhance stability to nuclease and improve cell uptake without affecting the hybridisation properties, which are vital for the efficient inhibitory properties of oligonucleotides. A large number of nucleic acid derivatives have been developed [5,7]. The conjugation of lipids to oligonucleotides, such as cholesterol [8,9], produces molecules with improved inhibitory properties [10,11].…”
Section: Introductionmentioning
confidence: 99%
“…These therapies include gene transfer and endogenous expression of recombinant proteins, 5,6 use of pegalated aptamers to bind and inhibit activity of excess VEGF 7 and oligonucleotide gene therapy. [8][9][10] Previously, we have reported on the discovery and use of a sense oligonucleotide (ODN-1) that is complimentary to a section of sequence in the 5 0 untranslated region of VEGF, for the inhibition of VEGF expression both in vitro and in vivo. We subsequently tested the efficacy of ODN-1 in reducing the extent of laser photocoagulation induced choroidal neovascularisation (CNV) in a rodent model.…”
Section: Introductionmentioning
confidence: 99%